TBNTech
The $15 billion ad-powered AI startup your doctor may already be using
Publication: Ars Technica - All content
Author: Rafe Rosner-Uddin, Financial Times
Source published: 21/10/2026, 15:14:07 UTC
Briefing created: 21/10/2026, 18:39:22 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 17:58:24 UTC.
Briefings
OpenEvidence, a Miami-based startup founded by Daniel Nadler in 2022, has achieved a $15 billion valuation by becoming the primary AI search engine for US doctors. The platform processes over 42 million prompts monthly from approximately 1 million physicians, primarily to access medical journals and clinical guidelines for diagnosis and treatment. Nadler describes it as the first viral consumer internet app in healthcare, growing largely through word of mouth rather than traditional marketing. The article notes that the startup is currently in a preprint phase with significant uncertainty regarding its long-term impact on patient care.
Key points
- OpenEvidence is a Miami-based startup founded by Daniel Nadler in 2022 that has reached a $15 billion valuation.
- The platform processes over 42 million prompts monthly from approximately 1 million US physicians to access medical journals and clinical guidelines.
Context
OpenEvidence represents a significant shift in how US doctors utilize technology, moving away from traditional tools toward an AI-powered search engine. This trend is notable because few other tools have achieved similar traction in the medical sector, and the startup's rapid growth suggests a potential future impact on patient care.
Limitations
The evidence is limited to a single article published in October 2026, which does not include additional background on the startup's history or the broader market context. The article explicitly states the startup is in a preprint phase, and the specific long-term impact on patient care remains uncertain.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 18:39:22 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeibknlf6ujzq3tq4bh35ajfwjean4h6sxecvfwgrnwvpmo7tbrjpnm